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Microparticles of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) and poly(ε-caprolactone) (PCL) containing resveratrol
were successfully prepared by simple emulsion/solvent evaporation. All formulations showed suitable encapsulation eﬃciency
values higher than 80%. PHBV microparticles revealed spherical shape with rough surface and presence of pores. PCL
microparticles were spherically shaped with smooth surface. Fourier-transformed infrared spectra demonstrated no chemical
bond between resveratrol and polymers. X-ray powder diﬀraction patterns and diﬀerential scanning calorimetry analyses
indicated that microencapsulation led to drug amorphization. These PHBV/PCL microparticles delayed the dissolution proﬁle
of resveratrol. Release proﬁles were better ﬁtted to biexponential equation. The hypochlorous-acid-scavenging activity and 2,2-
azinobis(3-ethylbenzothiazoline-6-sulfonic acid) radical cation discoloration assay conﬁrmed that the antioxidant activity of
PHBV/PCL microparticles was kept, but was dependent on the microparticle morphology and dissolution proﬁle. Resveratrol-
loaded PHBV/PCL microparticles showed no cytotoxic eﬀect on red blood cells.
1.Introduction
Oxidative damage occurs as an outcome of an imbalance
between the formation and inactivation of oxygen free
radicals and has a potential to have deleterious eﬀects [1].
Oxidativestressisincludedasamaincauseofseveralchronic
human diseases as cancer, diabetes, hypertension, cardiovas-
cular diseases, and aging [2]. The superoxide anion (O2
•−),
hydrogen peroxide (H2O2), and hydroxyl radical (OH
•)a r e
some of the reactive oxygen species (ROS) and can produce
(a) damage to cell membranes or other lipid structures
mostly by lipid peroxidation of unsaturated fatty acids, (b)
change in proteins by altering the tertiary structure and
leading to loss of function, fragmentation, and crosslinking,
and (c) changes in DNA which can be rearranged by repair
mechanisms or may induce mutations [1, 3].
Currently, there is a great interest in antioxidants mainly
due to the ﬁndings on the remarkable eﬀects of free radicals
in the human body. During an oxidative stress, the excess of
free radicals can be counteracted by antioxidants produced2 The Scientiﬁc World Journal
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Figure 1: Chemical structure of resveratrol.
endogenously or absorbed through the diet [4]. Considering
this perspective, resveratrol or trans-3,5,4 -trihydroxy-trans-
stilbene (Figure 1) is a phytoalexin produced by plants in
response to exogenous stress factors, such as injury, fungal
infections, or UV irradiation. It has been shown to be
a potent antioxidant, anti-inﬂammatory, anticancer, and
chemoprotective agent. It is reported that the possible
mechanismsforitsvariouspharmacologicalactivitiesinvolve
modulating lipid metabolism, platelet aggregation, and
inﬂammatory response [5–9]. The properties of resveratrol
are attributed to its ability to inhibit low-density lipoprotein
oxidation, while suppressing the activity of cyclooxygenase
2 and induced nitric oxide synthase also contributes to the
anti-inﬂammatory and antioxidant eﬀects [10]. This com-
pound can particularly aﬀect the process of carcinogenesis
in its three stages: initiation, promotion, and progression.
This drug has proved to be a suppressor of angiogenesis and
metastasis of tumors [11–14].
Despitethenumerousstudiesontheinvitropropertiesof
polyphenolic compounds, their suitable eﬀects are often not
observedinvivo.Thisdiﬀerencecanbepartiallyattributedto
a low absorption and a high metabolism of thesecompounds
that lead to a reduced in vivo result by oral administration as
compared to their great in vitro eﬃcacy [15]. Regarding the
resveratrol, its polyphenolic structure shows high hydropho-
bicity and it is sensitive to some external agents such as air,
light, and oxidative enzymes that can induce oxidation and
a light-induced conversion from the trans (Z) to the cis (E)
isomer and can reduce its viability and bioavailability for
clinical use [16–18].
Somerecentpapersaredevotedtoinvestigateresveratrol-
loaded micro-/nanoparticles in order to provide a con-
trolled release or to improve its stability and bioavailabil-
ity. Calcium-pectinate beads containing resveratrol were
prepared and showed a delayed release and a site-speciﬁc
delivery to the lower gastrointestinal tract [11]. Experimen-
tal parameters were studied to obtain resveratrol-loaded
poly(ε-caprolactone) nanoparticles with higher encapsu-
lation eﬃciency and lower particle sizes by oil-in-water
emulsion/solvent evaporation method [16]. Inclusion com-
plexes between trans-resveratrol and β-cyclodextrin or
hydroxypropyl-β-cyclodextrin revealed improved solubility
and kept the scavenging capacity against the stable radical
DPPH
• [19]. Resveratrol-loaded lipid-core nanocapsules
increased the concentration of trans-resveratrol in the
brain tissue and can be used for several brain diseases
including Alzheimer’s disease [20]. Pharmacokinetic studies
of resveratrol-loaded nanoparticles were performed and
demonstrated an increased systemic bioavailability [21].
Vanillin cross-linked chitosan microparticles showed a con-
trolled release of resveratrol [22].
Inspite of these papers, the literature does not re-
port studies involving resveratrol-loaded microparticles
obtained from poly(3-hydroxybutyrate-co-3-hydroxyvaler-
ate) (PHBV) and poly(ε-caprolactone) (PCL) as polymers.
T h e s ep o l y e s t e r sa r ea t t r a c t i v em a t e r i a l sf o rc o n t r o l l e d -
release drug applications due to their biodegradability. Their
decomposition products are not toxic and are easily excreted
[23]. Moreover, a lack of data is available regarding the
eﬀect of resveratrol-loaded microparticles on hemolysis
of red blood cells. Thus, the aim of this paper was to
obtain resveratrol-loaded PHBV/PCL microparticles by sim-
ple emulsion/solvent evaporation method and to evaluate
their erythrocyte cytotoxicity using the hemolysis assay in
order to investigate the feasibility of applying these polyester
microparticles as an oral drug delivery carrier for controlled
release.
2.MaterialsandMethods
2.1. Materials. trans-resveratrol (99.8% pure, Pharma
Nostra, Rio de Janeiro, Brazil), poly(3-hidroxybutirate-
co-3-hidroxyvalerate) (PHBV) (Mw = 380,000g·mol−1,
8.70mol% hydroxyvalerate, Biocycle L110, PHB Industrial,
Serrana, Brazil), poly(ε-caprolactone) (PCL) (Mw = 70,000–
90,000g·mol−1, Sigma-Aldrich, St. Louis, MO, USA), and
poly(vinyl alcohol) (PVA) (Mw = 72,000g·mol−1, 88.5mol%
of hydrolysis, Vetec, Rio de Janeiro, Brazil) were used as
received. The other reagents and solvents were of analytical
grade.
2.2. Preparation of Resveratrol-Loaded PHBV/PCL Micropar-
ticles. The polyester microparticles containing resveratrol
were prepared by simple emulsion/solvent evaporation pro-
cedure [23]. Three diﬀerent formulations (Table 1)w e r e
obtained for each polymer (PHBV/PCL) depending on the
amount of resveratrol into their compositions (5, 10, and
20%). Chloroform and methylene chloride were used as
polymer solvent for PHBV and PCL, respectively. Brieﬂy,
the organic phase was added into the aqueous phase under
mechanical stirring (5.000rev·min−1) for 5min. The emul-
sion was kept under mechanical stirring (800rev·min−1)
at room temperature for 4h. After evaporation of organic
solvent, microparticles were separated by centrifugation
(2.500rev·min−1, 10min), washed twice with puriﬁed water
and dried under vacuum at 35 ± 2◦C for 4h. The samples
were stored into a desiccator under vacuum at room temper-
ature. All formulations were obtained in triplicate. Unloaded
microparticles were also prepared as negative controls.
2.3. Residual Moisture. The water content of resveratrol,
PHBV, PCL, and microparticles was performed using an
infrared moisture analyzer (Top 160 Ray, Bel engineering,
Monza, Italy). For each sample, an amount of 1.000g was
placed on an aluminum plate and dried at 105◦C until
constant weight. The percentage corresponding to mass loss
was obtained as moisture content. The tests were carried out
in triplicate.The Scientiﬁc World Journal 3
Table 1: Composition of resveratrol-loaded PHBV/PCL microparticles.
Composition Formulation
R0 R5 R10 R20
Aqueous phase
Polysorbate 80 (g) 0.25 0.25 0.25 0.25
PVA (g) 4.00 4.00 4.00 4.00
Puriﬁed water (mL) 200.0 200.0 200.0 200.0
Organic phase
Resveratrol (g) — 0.10 0.20 0.40
PHBV (system M1) or PCL (system M2) (g) 2.00 1.90 1.80 1.60
Chloroform or methylene chloride (mL) 40.0 40.0 40.0 40.0
2.4. Characterization
2.4.1.DrugLoadingandEncapsulationEﬃciency. Anamount
of microparticles, equivalent to 20mg of resveratrol, was
weighed and magnetic stirred (1,000rev·min−1)w i t h7m L
ethanol for 12h. The volume was completed to 10mL
and ﬁltered through a poly(vinylidene ﬂuoride) membrane
ﬁlter (Durapore membrane, 0.22μm pore size, Millipore,
Bedford, MA, USA). After suitable dilution in ethanol, the
concentration of resveratrol was determined through HPLC
system (Waters Alliance 2695 HPLC System, Milford, MA,
USA) using a Waters XTerra C18 analytical column (250 ×
4.6mm, 5μm) with UV detection at 306nm, in triplicate.
Themobilephaseconsistedof0.2%(v/v)aceticacidinwater,
acetonitrile, and methanol (2.3:22.5:75v/v). The validation
of this HPLC method was previously performed through
the following parameters: linearity, limit of detection, limit
of quantitation, accuracy, robustness, precision, and speci-
ﬁcity [24]. The concentration range varied from 10.0 to
50.0μg·mL−1. Linearity was 0.99981, and the detection limit
was 172.18ng·mL−1. The encapsulation eﬃciency (EE) was
obtained using(1)
EE =
mass of resveratrol in microparticles
theoretical mass of resveratrol

×100. (1)
2.4.2. Scanning Electron Microscopy (SEM). The samples
were mounted on aluminum stubs, sputtered with gold
(IC-50 Ion Coater, Shimadzu, Kyoto, Japan), and analyzed
using a scanning electron microscope (SSX-550 Superscan,
Shimadzu, Kyoto, Japan) at an accelerating voltage of 10 or
15kV with diﬀerent magniﬁcations.
2.4.3. Particle Size and Size Dispersion. The particle size and
size dispersion of PHBV/PCL microparticles were measured
by laser diﬀraction spectrometry (LDS) in a Cilas 920L
apparatus (Marseille, France). The dried powder samples
were suspended in ﬁltered water and sonicated into the
ultrasonic bath coupled to the equipment for 1min before
measurements. Then, the mean diameters ± standard devi-
ations and the size distributions were determined. The span
was calculated using
span =
d(v,90) −d(v,10)
d(v,50)
,( 2 )
where d(v,10),d(v,50),a n dd(v,90) are the particle diameters
determined, respectively, at the 10th, 50th, and 90th per-
centile of the undersized particle distribution curve.
2.4.4. Fourier-Transformed Infrared Spectroscopy. The Fou-
rier-transformed infrared (FTIR) spectra of raw mate-
rials, PHBV/PCL microparticles, and physical mixtures were
recorded from 4000 to 400cm−1 on a Shimadzu IR Prestige-
21 spectrophotometer (Kyoto, Japan) using KBr pellets with
32 scans and resolution of 4cm−1.
2.4.5. X-Ray Powder Diﬀraction. Wide-angle X-ray powder
diﬀraction (XRPD) was performed with a Shimadzu X-ray
diﬀractometer (Shimadzu XRD-6000, Kyoto, Japan). The 2θ
was increased from 5◦ to 80◦ at a scan rate of 2◦·min−1 using
aC u - K α source (λ = 1.5418 ˚ A) at 40kV and 40mA.
2.4.6. Thermal Analyses
Thermogravimetric Analysis (TG). The thermogravimetric
curves were obtained in a thermobalance (TGA-50, Shi-
madzu, Kyoto, Japan) in the temperature range of 298–
1173K using platinum crucibles with 5.0 ±0.1mgofsample
under dynamic N2 atmosphere (ﬂow rate: 50mL·min−1)
and heat ﬂow of 10K·min−1. The equipment was previously
calibrated with copper sulphate pentahydrate.
Diﬀerential Scanning Calorimetry (DSC). DSC curves of
resveratrol, PHBV, PCL, physical mixtures, and micropar-
ticles were obtained in a DSC-60 calorimeter (Shimadzu,
Kyoto, Japan) using aluminum crucibles with 2.5 ± 0.1mg
of sample under dynamic N2 atmosphere (ﬂow rate:
50mL·min−1). The temperature range was 298–773K with
heating rate of 10K·min−1. An empty aluminum pan was
used as reference. The DSC cell was calibrated with indium
(m.p. = 429.6K; ΔHfusion = 28.54J · g−1) and zinc (m.p. =
692.6K).
2.5. In Vitro Drug Release. In-vitro release was carried out
for pure drug and resveratrol-loaded PHBV/PCL micropar-
ticles. Dissolution assays were performed in a Nova ´ Etica
dissolution tester (299/6, Vargem Grande Paulista, Brazil)
equipped with paddles (apparatus II) in 900mL of degassed4 The Scientiﬁc World Journal
Table 2: Mathematical models related to dissolution experiments.
Model Equation
Dissolution eﬃciency DE = (
 t
0 y · dt/y100 · t) ×100%
First-order %D = 100(1 −e−kt)
Biexponential %D = 100[1 −(Ae−αt +Be−βt)]
Zero-order %D = kt
Weibull %D = 100[1 −e−(t/TD)b]
Legend: %D: dissolved percentage, b:s h a p ep a r a m e t e r ,TD: time interval
necessary to release 63.2% of the drug, k, α and β: kinetics constants, t:
dissolution time, A and B: initial drug concentrations that contribute for
the two dissolution stages.
phosphate buﬀer solution (pH = 6.8, 50mmol·L−1 KH2PO4
and 22.4mol·L−1 NaOH) for 12h in triplicate. System was
kept at a thermostatically controlled temperature of 37 ±
0.5◦C and stirred at 75rev·min−1.A l le x p e r i m e n t sw e r e
heldunderdarkconditions.Atpredeterminedtimeintervals,
samples were collected (10mL), ﬁltered (0.45μmp o r e
size), and spectrophotometrically evaluated (Genesys 10S
spectrophotometer, Thermo Scientiﬁc, Madison, WI, USA)
at 306nm. The dissolution value was obtained from the
amount of drug released. A correction factor was applied to
the cumulative dilution caused by replacement of the sample
with an equal volume of fresh medium.
2.5.1. Analysis of Release Behavior. Dissolution proﬁles of
resveratrol and PHBV/PCL microparticles were compared
by independent and dependent methods as summarized
in Table 2. As model-independent analysis, dissolution
eﬃciency,theareaunderadissolutioncurvebetweendeﬁned
time points [25], was used. Proﬁles were also investigated
bymodel-dependentmethodsusingtheMicroMathScientist
2.01 software (Salt Lake City, UT, USA). Data were tested
to ﬁt ﬁrst-order, biexponential, zero-order, and Weibull’s
equations (Table 2)[ 26]. The selection of model-dependent
method was based on the best correlation coeﬃcient (r), the
best model selection criteria (MSC), and the best graphic
adjustment.
In order to have some insight into the drug release
mechanism, a very simple and semiempirical equation to
describe drug release from polymeric systems, the power law
(Korsmeyer-Peppas model) [27], was also applied
ft= atn (3)
where ft is the drug dissolved fraction at time t,n is the
release exponent, indicative of the mechanism of the drug
release, and a is the constant incorporating structural and
geometric characteristics of the drug dosage form.
2.6. Antioxidant Potential. In order to compare the antiox-
idant capacity of pure resveratrol and resveratrol-loaded
microparticles, the antioxidant potential was evaluated by
hypochlorous-acid- (HOCl-) scavenging assay and 2,2-azi-
nobis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radi-
cal cation discoloration. Aqueous solutions of pure drug and
loaded microparticles (M1R20/M2R20) containing the same
concentrations of resveratrol were prepared 30min before
start of experiments and kept under dark conditions.
2.6.1. HOCl Scavenging Activity. After 5min of react-
ing 75μmol·L−1 HOCl (30μL) with each aqueous solu-
tion (20μL) of pure drug or loaded microparticles
(M1R20/M2R20), a volume of 20μL of a solution contain-
ing 10mmol·L−1 3,3 ,5,5 -tetramethylbenzidine (TMB) dis-
solved in 50% dimethylformamide, 100μmol·L−1 potassium
iodide and 400mmol·L−1 acetic acid was added [28]. The
reaction was performed in 50mmol·L−1 sodium phosphate
buﬀer solution (pH = 7.4) to a ﬁnal volume of 200μLa t
37◦C for 15min. The absorbance was recorded at 650nm
in a microplate reader (SpectraMax 190 spectrophotometer,
Molecular Devices, Sunnyvale, CA, USA). All measurements
were performed in triplicate, and unloaded-microparticles
(M1R0/M2R0) were used as negative control. The antioxi-
dant activity was obtained as percentage of HOCl inhibition
using
% inhibition =
(Ab −Aa)
Ab

×100 (4)
where Ab is the absorbance of the control and Aa is the
absorbance of the sample.
2.6.2. ABTS Radical Cation Discoloration Assay. In brief,
aqueous solutions of 7mmol·L−1 ABTS and 2.45mmol·L−1
potassium persulfate were mixed in a volume ratio of 1:1
and incubated in dark at room temperature for 12h to
obtain ABTS•+ [29]. The ABTS•+ solution was diluted to
an absorbance value of ±0.7 at 734nm in 50mmol·L−1
sodium phosphate buﬀer solution (pH = 7.4). The reduction
between ABTS•+ and pure drug or loaded microparticles
(M1R20/M2R20) was measured by decreasing absorbance
at 734nm after 30min in a microplate reader (SpectraMax
190 spectrophotometer, Molecular Devices, Sunnyvale, CA,
USA). All measurements were performed in triplicate,
and, unloaded microparticles (M1R0/M2R0) were used as
negative control. The antioxidant activity was calculated as
percentage of ABTS•+ inhibition according to (4).
2.7. Erythrocyte Hemolysis Assay. The in vitro cytotoxic eﬀect
of pure resveratrol and PHBV/PCL microparticles was stud-
ied using heparinized venous blood samples collected from
healthy volunteers. This experiment involving human blood
wasapprovedbytheEthicsCommitteeoftheStateUniversity
of Ponta Grossa.
Fresh blood was centrifuged (4000rev·min−1 for 5min)
at 4◦C using a refrigerated centrifuge, and the plasma
and buﬀy coat were carefully removed by aspiration. The
red blood cells were washed three times by centrifugation
(4000rev·min−1 for5min)incoldphosphatebuﬀersolution
(0.15mmol·L−1 NaCl, 50mmol·L−1 NaH2PO4/Na2HPO4,
pH = 7.4). The red blood cells were ﬁnally resuspended with
the same buﬀer to obtain a hematocrit of 5% [30].
Freshly prepared aqueous solutions (10μL) of pure
drug or loaded microparticles (M1R20/M2R20) containing
the same concentration of resveratrol (71μg·mL−1)w e r eThe Scientiﬁc World Journal 5
Table 3: Water content1, resveratrol entrapped into microparticles1, encapsulation eﬃciency (EE)2, particle size, and span for PHBV/PCL
microparticles.
Microparticles Water content (%) Resveratrol-loaded (mg·g−1) EE (%) Mean diameter (μm) Span
M1R0 1.29 ± 0.11 — — 25.23 2.38
M1R5 1.50 ± 0.09 46.43 ±1.77 93 47.00 1.88
M1R10 1.10 ± 0.08 83.80 ±2.41 84 33.75 2.25
M1R20 1.40 ± 0.12 159.30 ±2.72 80 29.20 2.27
M2R0 1.57 ± 0.13 — — 33.97 1.33
M2R5 1.56 ± 0.11 50.63 ±1.61 101 52.09 1.27
M2R10 1.09 ± 0.08 89.41 ±2.03 89 52.84 1.37
M2R20 1.55 ± 0.14 176.70 ±2.55 88 55.73 1.76
1mean (n = 3) ± standard deviation; 2mean (n = 3).
incubated in triplicate at 37◦C with a 5% red blood cell
suspension (450μL) and the previously prepared phosphate
buﬀer solution (40μL) for 24h under constant shaking at
120 rev·min−1. The red blood cell suspension was then
centrifuged at 4000 rev·min−1 for 5min. Hemolysis was
determined by measuring the absorbance at 540nm in
a microplate reader (SpectraMax 190 spectrophotometer,
Molecular Devices, Sunnyvale, CA, USA) [31, 32]. Tests were
also carried out for unloaded-microparticles (M1R0/M2R0).
Hemolysis observed in the absence of sample was taken
as blank. Groups were compared using one-way ANOVA
followedbyTukey’spost hoc test.A P valueof ≤0.05 wasused
to indicate statistically signiﬁcant diﬀerences.
3. Results andDiscussion
The polyester microparticles were successfully prepared by
simple emulsion/solvent evaporation method. After drying,
PHBV microparticles (system M1) showed powder aspect
and pale yellow color similar to PHBV. For PCL micropar-
ticles (system M2), powder aspect and oﬀ-white color were
observed. Water contents of 1.20 ± 0.12%, 3.59 ± 0.17%,
and 1.12 ± 0.09% were obtained for pure resveratrol, PHBV
and PCL, respectively. Microparticles showed only residual
moisture values as presented in Table 3. These data demon-
strate that the performed vacuum drying was able to remove
the water used during microencapsulation. The residual
water content in a powder inﬂuences its physical stability
and controls the magnitude of capillary forces that hold
particlesinaggregates[33].Consideringtheobtainedresults,
it is possible to establish that the water content exhibits
little interference in the physical stability of PHBV/PCL
microparticles.
3.1. Drug Loading and Encapsulation Eﬃciency. The drug
content and encapsulation eﬃciency for the prepared
microparticles are also summarized in Table 3.H i g hp e r -
centages of drug entrapment were obtained for PHBV/PCL
microparticles by simple emulsion/solvent evaporation. All
formulations showed suitable EE values higher than 80%.
Thesevaluesaremainlybasedonthepooraqueoussolubility
(13.6μg·g−1 in pH = 7.4) of resveratrol [34] which leads to
an increase in the drug loaded into microparticles. Similar
results were previously reported. A resveratrol entrapment
higher than 97.7% was achieved for calcium-pectinate
beads prepared by instantaneous gelation of pectin [11].
Resveratrol-loaded nanoparticles showed EE from 78.3 to
91.4% using PCL of Mw = 65,000g·mol−1 [16]. Vanillin
cross-linked chitosan microparticles containing resveratrol
revealed a drug entrapment higher than 93.7% [22].
The polymer:drug ratio is also a critical factor during
microparticle formation and can inﬂuence EE values [35].
The enhancement of resveratrol entrapment was observed
when the polyester amount was increased (Table 3). For
PHBV microparticles, EE was increased from 80 to 93% as
polymer:drug ratio was improved from 4:1 (20% resver-
atrol) to 19:1 (5% resveratrol). Resveratrol entrapment
varied from 88 to 101% for PCL microparticles when
polymer:drug ratio was changed at the same proportion.
This eﬀect can be simply due to the greater polymer with
respect to the drug amount.
3.2. Scanning Electron Microscopy. The scanning electron
micrographs of PHBV/PCL microparticles are shown in
Figure 2.D i ﬀerent morphological aspects were observed
depending on the polyester used. By SEM, PHBV micropar-
ticles were spherical shaped with a rough surface and
pores (Figures 2(a)–2(d)). The presence of pores represents
important morphological evidence that can change the
drug release process from microparticles [36]. However,
PCL microparticles revealed a spherical shape with smooth
surface (Figures 2(e)–2(h)), and no pore were observed.
Moreover, formulation M2R20 showed a residual resveratrol
onto the microparticles surface. This external drug can be
rapidly dissolved into an aqueous medium and provide an
immediate-release behavior (burst eﬀect) [23]. This eﬀect
has been also observed in other studies related to delayed-
release biopolymer systems [37, 38].
3.3. Particle Size and Size Dispersion. The particle size
and size distribution obtained by LDS measurements are
indicated in Table 3. Micrometer-sized particles with mean
diameters less than 60μm were obtained. Although these
particle sizes do not allow an uptake by intestinal tissue,
the oral administration of these microparticles can provide
sustained drug eﬀect due to their prolonged bowel transit6 The Scientiﬁc World Journal
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Figure 2: Scanning electron micrographs of PHBV/PCL microparticles: M1R0 (a), M1R5 (b), M1R10 (c), M1R20 (d), M2R0 (e), M2R5 (f),
M2R10 (g), and M2R20 (h). Magniﬁcations of 2000x.
time[39].Regardingthatalow spanvalueindicates anarrow
polydispersity [40], PCL microparticles presented a more
homogeneous size distribution when compared to PHBV
microparticles.
3.4. Fourier-Transformed Infrared Spectroscopy. FTIR spectra
performed for resveratrol, PHBV, PCL, physical mixtures,
and PHBV/PCL microparticles are shown in Figure 3.T h e
FTIR spectrum of pure resveratrol showed a typical OH-
stretching band at 3257cm−1 and three intense bands at
1610, 1589, and 1385cm−1 corresponding to C–C aromatic
double-bond stretching, C–C oleﬁnic stretching, and C–O
stretching. The typical trans oleﬁnic band was observed at
965cm−1 [5]. PHBV infrared spectrum exhibited a strong
band at 1720cm−1 due to C=O stretching. Typical bands
from 800 to 975cm−1 corresponded to symmetric–C–O–C–
stretching vibration. Moreover, the antisymmetric–C–O–C–
stretching leads to bands between 1060 and 1150cm−1 [35].
Considering PCL is also an aliphatic polyester, its spectrum
is similar to that of PHBV with a strong band at 1727cm−1
corresponding to C=O stretching and two bands at 2943
and 2864cm−1 due to symmetric and asymmetric CH2-
stretching, respectively [41].
Physical mixtures and microparticles presented band
assignments at the same wavenumber range of FTIR spec-
trum. Therefore, no diﬀerence in the positions of the
absorption bands was observed between resveratrol-loaded
microparticles and respective physical mixtures. Conse-
quently, no chemical bond between drug and polymers was
formed during microencapsulation.
3.5. X-Ray Powder Diﬀraction. Figure 4 shows the XRPD
patterns of resveratrol, PHBV, PCL, physical mixtures,
and PHBV/PCL microparticles. Pure resveratrol presented
diﬀerent peaks related to a crystalline structure, and its
main peaks appear at 2θ = 6.62, 16.30, 19.17, 22.43,
23.55, and 28.37. Resveratrol-loaded microparticles revealed
XRPD patterns similar to pure PHBV/PCL and unloaded-
microparticles (M1R0/M2R0). These results suggest that
the microencapsulation procedure provided a remarkable
decrease of the crystalline diﬀraction peaks of resveratrol
leading to drug amorphization [42].The Scientiﬁc World Journal 7
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Figure 3: FTIR spectra of resveratrol, PHBV/PCL, physical mixtures, and PHBV/PCL microparticles.
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Figure 4: XRPD patterns of resveratrol, PHBV/PCL, physical mixtures, and PHBV/PCL microparticles.
Substances in solid state can reveal crystalline and/or
amorphous characteristics. In general, amorphous solids are
more soluble than crystalline forms due to free energies
involved in the dissolution process. Solids in amorphous
statehaverandomlyarrangedmolecules,andthuslowenergy
is required to separate them. Consequently their dissolution
is faster than when in the crystal form [43].
3.6. Thermal Analyses
3.6.1. Thermogravimetric Analysis. T h eT Gc u r v e so fp u r e
resveratrol, PHBV, PCL, physical mixtures, and PHBV/PCL
microparticles are shown in Figures 5 and 6.R e s v e r a t r o l
presented two events of weight loss that can be observed
through its derivative thermogravimetric curve (DTG). The
ﬁrst event ranged from 625 to 758K (Δm = 41.7%), while
the second one occurred between 758 and 1150K (Δm =
57.5%).Bothpolymersshowedonlyoneeventofweightloss,
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Figure 5: TG and DTG curves of resveratrol.
ranging from 564 to 591K (Δm = 97.6%) for PHBV and
from 639 to 734K (Δm = 97.7%) for PCL.
PHBV microparticles demonstrated onset temperatures
of degradation at 585, 581, 577, and 582K for M1R0,8 The Scientiﬁc World Journal
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Figure 6: TG curves of resveratrol, PHBV/PCL and physical mixtures (a) and (b), PHBV microparticles (c), and PCL microparticles (d).
M1R5, M1R10, and M1R20, respectively. Otherwise PCL
microparticles started their degradation at 671K (M2R0),
689K (M2R5), 686K (M2R10), and 683K (M2R20). These
results indicate that PCL microparticles are thermally more
stable than those composed by PHBV. Similar data were
previously described for carvedilol-loaded microparticles,
in which formulations containing PCL revealed increased
thermal stability than formulations prepared with PHBV
[23].
3.6.2. Diﬀerential Scanning Calorimetry. DSC curves of pure
resveratrol, PHBV, PCL, physical mixtures, and PHBV/PCL
microparticles are indicated in Figure 7. Resveratrol showed
a sharp endothermic event at 539K in accordance with
the literature values [44, 45]. The melting temperatures
(Tm) obtained for polymers were 438K for PHBV and
333K for PCL, conﬁrming previously reported data [41].
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Figure 7: DSC curves of resveratrol, PHBV/PCL, physical mixtures,
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Figure 8: In vitro release proﬁles of pure drug and resveratrol-loaded PHBV/PCL microparticles.
The typical melting event of resveratrol was not observed
in DSC curves of PHBV/PCL microparticles. This thermal
behavior suggests that a drug amorphization occurred. This
result is reinforced by the XRPD patterns of PHBV/PCL
microparticles in which only the characteristic crystalline
peaks of the polymers were observed.
3.7. In Vitro Drug Release and Analysis of Release Behav-
ior. The dissolution rates of resveratrol and PHBV/PCL
microparticles are shown in Figure 8. By the performed
dissolution test, the mean time for 80% release of pure
resveratrol was 45min. However, PHBV microparticles
demonstrated mean dissolution times of 300min (M1R5),
240min (M1R10), and 90min (M1R20) for 80% drug
release. For PCL microparticles, a value of 80% drug release
was achieved in mean dissolution times of 720, 300, and
180min for M2R5, M2R10, and M2R20, respectively. There-
fore resveratrol from PHBV/PCL microparticles showed a
slower dissolution rate than pure drug.
These results demonstrate that PHBV/PCL played an
important role on the delay of drug dissolution. This behav-
ior can be related to polymer:drug ratio and morphological
aspects. For both PHBV/PCL microparticles, formulations
obtained at a polymer:drug ratio of 19:1 (5% resveratrol)
showed slower release of resveratrol. Probably the greater
amount of polyester in these formulations had a remarkable
eﬀect in controlling the drug release rate. This faster release
of resveratrol from PHBV microparticles can also be related
to their porous surface previously observed by SEM. In
general, microparticle studies have showed that the drug
release rate is faster for higher-porosity materials [41].
Regarding the dissolution eﬃciency (DE), microparticles
decreased this value extensively. Whereas the pure drug pre-
sented a DE of 96.2% along 720 minutes, PHBV micropar-
ticles showed DE of 73.3% (M1R5), 78.6% (M1R10), and
88.9% (M1R20). For PCL microparticles, DE of 52.2, 78.0,
and 85.0% was obtained for M2R5, M2R10, and M2R20,
respectively. Previous papers reported that a high DE was
veriﬁed for pharmaceutical dosage forms of immediate
release while a lower value was indicative of a controlled
release behavior [46, 47].
The release proﬁles were ﬁtted to mathematical models,
andtheselectionofthebestmodelconsideredthecorrelation
coeﬃcient (r), the model selection criteria (MSC), and the
graphic adjustment. Resveratrol and PHBV/PCL microparti-
cles were better ﬁtted to the biexponential equation (Table 4)
than other models. The burst-release apparent rate constant
(α) and the slow-release apparent rate constant (β)f o r
resveratrol and PHBV/PCL microparticles are reported in
Table 4.
These results demonstrated that PHBV/PCL microparti-
cles reduced the drug dissolution rate, nevertheless without
changing its release model. The ﬁrst stage of release was
initially rapid (burst release) whereas the second stage of
release was slow (controlled release). The burst release can
helptoreachtheeﬀectiveconcentrationofresveratrolrapidly
in plasma, whereas the controlled release would maintain
the eﬀective concentration of drug in plasma for a long
time [22]. Moreover the poor bioavailability of resveratrol
due to its rapid metabolism, including its conjugation with
sulfate in the intestinal mucosa, and elimination could be
partially avoided by microencapsulation, thus prolonging its
biological half-time in vivo.
Concerning the mathematical modeling ﬁtting the
Korsmeyer-Peppas model, PHBV microparticles showed n
values of 1.23 (M1R5), 0.89 (M1R10), and 1.28 (M1R20).
For PCL microparticles, n values of 0.65, 0.57, and 0.73
were obtained for M2R5, M2R10, and M2R20, respectively.
PHBV microparticles presented values of n greater than
0.85 indicating that the release mechanism is governed
by erosion [27]. Considering that PHBV is an aqueous-
insoluble polymer, the process can occur by sequential10 The Scientiﬁc World Journal
Table 4:ReleasedataobtainedbyﬁttingthedissolutionproﬁlesofpureresveratrolandPHBV/PCLmicroparticlestothebiexponentialequa-
tion.
Material Biexponential model
MSC R α (min−1) β (min−1)
Resveratrol 5.45 0.9988 0.9902 0.8262
M1R5 5.30 0.9984 0.0357 0.0054
M1R10 5.23 0.9982 0.0082 0.0082
M1R20 4.26 0.9953 0.0360 0.0042
M2R5 2.18 0.9616 0.0693 0.0014
M2R10 4.32 0.9956 0.0465 0.0044
M2R20 4.18 0.9949 0.0363 0.0066
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Figure 9: Antioxidant eﬀect of pure resveratrol, and PHBV/PCL microparticles by HOCl- (a) and ABTS•+- (b) scavenging activity.
stages of entrance of water and drug release. Otherwise
PCL microparticles revealed values of n b e t w e e n0 . 4 3a n d
0.85. These intermediate values are related to an anomalous
behavior, a non-Fickian kinetics corresponding to the super-
position of diﬀusion and erosion phenomena [27].
3.8. Antioxidant Potential. In order to explore whether the
microencapsulation has inﬂuence on antioxidant capacity
of resveratrol, HOCl-scavenging activity and ABTS radical
cationdiscolorationassayofpureresveratrolandresveratrol-
loaded microparticles at the same drug concentrations were
compared.
The HOCl-scavenging potential of pure resveratrol and
PHBV/PCL microparticles is presented in Figure 9(a).
Resveratrol (IC50 = 0.08μg·mL−1)a n dM 1 R 2 0( I C 50 =
3.03μg·mL−1) showed higher eﬀect on HOCl scavenging
activity,andwerefollowedbyM2R20(IC50 =9.84μg·mL−1).
In biological systems, HOCl is the most toxic and abun-
dant oxidizing agent produced by polymorphonuclear neu-
trophils. It can also attack important biological molecules
and generate other harmful ROS.
The results for ABTS radical cation discoloration test are
shown in Figure 9(b). Considering ABTS•+- scavenging po-
tential, a higher activity was obtained for resveratrol (IC50 =
2.79μg·mL−1)a n dM 1 R 2 0( I C 50 = 11.85μg·mL−1). An
IC50 value of 21.50μg·mL−1 was observed for formulation
M2R20. This assay is widely used for screening the antiox-
idant properties of diﬀerent compounds and reﬂects their
capacity to donate electrons or hydrogen for inactivating
this radical. In both assays, the unloaded microparticles pre-
sented a negligible antioxidant eﬀect.
Regarding the studied concentrations, pure drug and
resveratrol-loaded PHBV/PCL microparticles showed diﬀer-
ent eﬃciencies in scavenging capacity. Although the resultsThe Scientiﬁc World Journal 11
indicated a lower antioxidant activity for resveratrol from
PHBV/PCL microparticles, it is important to remember that
scavengingassayswereperformedabout1hafterpreparation
of aqueous solutions under test, and resveratrol entrapped
into polyester microparticles was not completely available to
react with oxidizing agents. Therefore PHBV/PCL micropar-
ticles have an antioxidant eﬀect even more promising for
pharmaceutical purposes than pure drug because of their
potentialasacontrolled-releasecarrierforprolonginginvivo
bioavailability of resveratrol. In Despite its high antioxidant
activity, pure resveratrol can present a less appropriate
behavior biologically due to its rapid metabolism and
elimination.
Morphology of PHBV/PCL microparticles and drug dis-
solution rate are also strongly related to these antioxidant
activities. PHBV microparticles had porous surface which
can provide a faster release of resveratrol as compared to
PCL microparticles. This porous aspect can also permit a
better access of oxidizing species to the resveratrol entrapped
into PBHV microparticles. These antioxidant values are in
accordance to the in vitro drug release proﬁles, since PCL
microparticles revealed the slower dissolution rate.
Diﬀerent data were previously reported for inclusion
complexes between trans-resveratrol and β-cyclodextrin or
hydroxypropyl-β-cyclodextrin that showed minor diﬀer-
ences on scavenging capacity against an artiﬁcial oxidant,
DPPH• [19]. Otherwise the scavenging activity of resveratrol
was reduced when lipid emulsion and aqueous micelle
system were prepared [34].
Thus, it is possible to suggest that the resveratrol-loaded
PHBV/PCL microparticles oﬀer a feasible system to control
resveratrol release as result of keeping its antioxidant eﬀect.
3.9. Erythrocyte Hemolysis Assay. Hemolysis assay is a fast,
eﬃcient, simple, and low-cost procedure to investigate the
cytotoxicity of micro-/nanoparticles on erythrocytes mem-
brane by spectrophotometric measurement of the released
hemoglobin[48].TheobtainedresultswerepresentedinFig-
ure 10. Regarding the hemolysis values, pure resveratrol and
PHBV/PCL microparticles showed no signiﬁcant diﬀerences
to blank (P>0.05). These data support that pure drug and
PHBV/PCL microparticles particularly have compatibility
with erythrocytes. A statistically signiﬁcant diﬀerence was
only observed between resveratrol and formulation M1R0
(P = 0.0467).
According to the literature, resveratrol exhibited no
hemolytic eﬀe ctt oh u m a nr e db l o o dc e ll su pt o1 0 0μg·mL−1
of concentration [49]. However no previous paper per-
formed the erythrocyte hemolysis assay of resveratrol-
loaded and resveratrol-unloaded PHBV/PCL microparticles.
Therefore this cytotoxicity assay results demonstrate that the
obtained polyester microparticles have no hemolytic proper-
ties on human red blood cells which indicate their potential
for pharmaceutical and biotechnological applications.
4. Conclusion
Polyester microparticles containing resveratrol were suc-
cessfully prepared by simple emulsion/solvent evaporation.
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Figure 10: Absorbance values resulting from the released hemo-
globin in erythrocyte hemolysis assay for blank, pure resveratrol,
and PHBV/PCL microparticles. The asterisk indicates statistically
signiﬁcant diﬀerence (P = 0.0467).
High drug-loading eﬃciencies were obtained for PHBV/PCL
microparticles. Morphological data played a crucial role in
evaluating the drug release. Fourier-transformed infrared
spectra indicated no chemical bond between resveratrol and
polymers. X-ray powder diﬀraction patterns and diﬀerential
scanning calorimetry analyses demonstrated that microen-
capsulation led to a drug amorphization. PHBV/PCL mi-
croparticles provided a substantial decrease of dissolution
rate of resveratrol without changing its biexponential release
model. The antioxidant potential of resveratrol entrapped
into PHBV/PCL microparticles was kept, but was dependent
on the microparticle morphology and dissolution proﬁle.
PHBV/PCL microparticles showed no cytotoxic eﬀect on red
blood cells. These results support an experimental basis for
the use of resveratrol-loaded PHBV/PCL microparticles as
a feasible oral drug delivery carrier for controlled release of
resveratrol, being an attractive alternative in chronic diseases
prevention.
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